Clinical trial NCT01755325: Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+
Official title: Phase III Study of Compound Realgar Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult Patients With Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE3
Conditions: Chronic Myelogenous Leukemia
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2012-12-24
Enrollment: 680
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It is an open-label, randomized, double blind, placebo-controlled parallel-group, multi-center study to evaluate the efficacy and safety of Compound realgar formula Realgar-Indigo naturalis Tablet combined with Imatinib will be compared with imatinib alone in adult patients with diagnosed Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in the chronic phase (CML-CP).


Eligibility criteria: Inclusion Criteria:

1. Male or female patients, age \>= 18 years and \<= 75 years.
2. Eastern Cooperative Oncology Group （ECOG） performance status (PS) score 0, 1, or 2.
3. Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome positive.(Ph+ CML-CP)
4. Ph+ Chronic myelogenous leukemia in chronic phase patients within the first 12 months of diagnosis.
5. Adequate end organ function as defined by:

(1). Alanine transaminase（ALT）, Aspartate transaminase（AST） \<=2.5 x upper limit of normal（ULN）.

(2). Total bilirubin \<= 1.5 x ULN. (3).Cr \<= 1.5 x ULN. (4). Serum amylase and lipase \<= 1.5 x ULN. 6. Signed informed consent.

Exclusion Criteria:

1. Previously received or be receiving any of the following medical treatment for CML:

1. . Treatment with Busulfan within 1 day prior to study entry.
2. . Treatment with interferon-alpha within 2 days prior to study entry.
3. . Treatment with hydroxyurea within 1 day prior to study entry.
4. . Treatment with homoharringtonine within 14 days prior to study entry.
5. . Treatment with Cytosine arabinoside within 28 days prior to study entry.
6. . Surgery (Including hematopoietic stem cell transplantation therapy)
7. . Treatment with anthracyclines, or etoposide within 21 days prior to study entry.

2. Treatment with any tyrosine kinase inhibitor(s) or arsenic reagent prior to study entry 3. Patients who are: (a) pregnant, (b) breast feeding, (c) female or male of childbearing potential unwilling to use contraceptive precautions throughout the trial.

4. Major surgery within 4 weeks prior to randomization or who have not recovered from prior surgery.

5. Patients who have not recovered from toxic reaction of prior similar treatment evaluated by investigators.

6. Impaired cardiac function including any one of the following:

1. LVEF \< 45%.
2. . Complete left bundle branch block.
3. . Use of a ventricular-paced pacemaker.
4. . Congenital long QT syndrome.
5. . History or presence of ventricular, clinically significant atrial tachyarrhythmias
6. . History or presence of clinically significant bradyarrhythmia.(heart rate persistently less than 50/min)
7. . QTcF \> 450 msec for male or 470 msec for female.
8. . History of clinically documented myocardial infarction or unstable angina (during the last 12 month).
9. .Any other severe heart disease. 7. Patients with active, uncontrolled psychiatric disorders, without insight and the ability of exact expression.

8. Uncontrolled medical conditions:

1. .Uncontrolled diabetes with fasting blood-glucose \>200mg/dl (11.1mmol/L),or with combined symptoms (nephropathy, peripheral neuropathy).
2. . Uncontrolled hypertension.
3. . Active or uncontrolled infection (persistent fever and worsening of the clinical symptoms) 9. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the tested drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery).

10. History of chronic pancreatitis or history of acute pancreatitis within 1 year of study entry.

11. Acute or chronic uncontrolled liver disease or severe renal disease considered unrelated to CML.

12. Patients actively receiving therapy with strong CYP3A4 inhibitors, strong CYP3A4 inducers or any medications being potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.

13. Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks prior to randomization.

14. Known to be allergic to the study drugs, including crude drug or adjuvant. 15. As investigators evaluate, the patients do not fit to join the study (such as with severe complications) .

Primary outcomes:
measure: To compare the rate of Major molecular response（MMR） at 12 months
timeFrame: 12 months of follow-up from the start of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Union Hospital medical college Huazhong University of Science and Technology
state: Hubei
city: Huaian
country: China
facility: The NO.1 People's Hospital of Huaian
state: Jiangsu
city: Nanjing
country: China
facility: The First Affiliated Hospital with Nanjing Medical University
state: Jiangsu
city: Suzhou
country: China
facility: First Hospital Affiliated to Suzhou University
state: Jiangsu
city: Nanchang
country: China
facility: The FIrst Affiliated Hospital, College of Medicine, Nanchang University
state: Jiangxi
city: Nanchang
country: China
facility: The Second Affiliated Hospital, College of Medicine, Nanchang University
state: Jiangxi
city: Nanchang
country: China
facility: The Tumor Hospital of Jiangxi
state: Jiangxi
city: Nanchang
country: China
facility: The NO.1 Hospital of Nanchang
state: Jiangxi
city: Dalian
country: China
facility: The Second Affiliated Hospital of Dalian Medical University
state: Liaoning
city: Xi'an
country: China
facility: Xijing Hospital-Fourth Military Medical University
state: Shanxi
city: Hangzhou
country: China
facility: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
state: Zhejiang
city: Peking
country: China
facility: The People's Hospital of Peking University
city: Shanghai
country: China
facility: Ruijin Hospital
Study officials:
affiliation: Runjin Hospital
name: Saijuan Chen, M.D.
role: STUDY_CHAIR
References: